Improved aspiration systems, large-bore catheters, balloon-guide catheters and radial access top the list of neurovascular device trends that will continue in 2022.

In the market for mechanical thrombectomy devices, the pace of innovation shows no signs of slowing down in 2022. Manufacturers are designing neurointerventional devices with an eye toward improving first-pass effect, recanalization rates and reducing procedure times to ultimately improve patient outcomes In this article, SmartTRAK highlights recent trends in neurovascular technologies, including variable pressure aspiration systems, large-bore catheters (LBCs), balloon-guide catheters (BGCs) and radial access, as key areas of innovation moving into 2022.

Along with the recent trends in neurovascular technologies, the following topics are covered in detail in this article, which is available for download here:

• Outgrowing Standard Aspiration Systems
• Continued Trend Toward Large-Bore Catheters for Access and Aspiration
• New Designs and Applications for Balloon-Guide Catheters
• Increasing Competition in Radial Access

Wallaby Medical CEO and founder Michael Alper discusses the Company’s recent acquisition of phenox GmBH and positioning the Company for success in an interview with SmartTRAK

With no overlap from a product or geographic perspective, Wallaby Medical’s recent acquisition of phenox GmBH was a “match made in heaven” according to Wallaby’s CEO and founder Michael Alper. In an interview with SmartTRAK, Alper discusses the acquisition, company synergies, complementary channels and the Company’s strategies for global expansion and becoming a leader in the market for neurovascular intervention.

To find out more, including details about the acquisition, the Company and its key products and markets, click on the following video to listen to the interview recorded via Zoom (21:07 min). A link to download the complete transcript of the interview is also provided below.

Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming, in an in-depth interview with SmartTRAK at INS 2022

Rafael Carbunaru, PhD, vice president of research and development for Boston Scientific (BSX), discusses deep brain stimulation (DBS) and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming in an in-depth interview with SmartTRAK at the International Neuromodulation Society (INS) World Congress in Barcelona, Spain held May 21-26.

Used with the Vercise Genus DBS portfolio and developed in collaboration with Brainlab, STIMVIEW XT uses patient-specific 3D visualization of patient anatomy and enables clinicians to see, shape and steer DBS therapy using point-and-click interface designed to simplify programming, save time and better personalize therapy.

To find out more about STIMVIEW XT, DBS workflows and BSX’s vision for DBS, click on the following video to listen to the interview recorded live at INS 2022 (45:16 min). For more details, interview topics by timecode are provided below. A link to download a complete transcript of the interview is also available below.

Among the many topics covered in detail in our comprehensive Q122 Spinal Cord Stimulation Market Recap* are:

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with SmartTRAK at INS 2022

Dr. Marc Russo discusses dorsal horn dendrite stimulation, a new paradigm for SCS, and making it available to all manufacturers in an interview with SmartTRAK at INS 2022

Dr. Marc Russo, president of the International Neuromodulation Society (INS), presented exciting new research on dorsal horn dendrite stimulation (DHDS), a new paradigm for spinal cord stimulation (SCS), at the INS 15th World Congress, held May 21 to 26, 2022 in Barcelona, Spain. In an interview with SmartTRAK, Dr. Russo discusses the proposed mechanism of action for DHDS compared to traditional dorsal column stimulation, six-month study results in 27 patients and what’s next in terms of his research. 

And, in an unprecedented move, Dr. Russo decided not to patent DHDS and said he is giving the novel waveform as a “gift” to physicians, industry and patients, noting that it is deployable on all current SCS devices within the product range. To find out more about DHDS, including its characteristics and Dr. Russo’s vision for a more advanced version that could theoretically even “cure pain,” click on the video below of the interview conducted shortly after his presentation outside the Barcelona International Convention Centre (12:02 min). A link to download the  complete transcript of the interview is also provided below.

In the market for neuromodulation, companies are developing spinal cord stimulation (SCS), deep brain stimulation (DBS) and other stimulation devices designed to treat a vast range of indications. Current and emerging devices are addressing care gaps in the treatment of chronic pain and movement disorders as well as epilepsy, Tourette syndrome, depression, pelvic floor dysfunction, peripheral artery disease, paralysis and spinal cord injuries.

Companies competing in the market for neuromodulation include Abbott*, Boston Scientific*, Medtronic*, Nevro*, Saluda Medical*, Newronika* and Axonics, just to name a few. To keep you up to speed on what’s new in neuromodulation, SmartTRAK highlights market updates covering clinical developments, patents, new research and other top news from Spring 2022.

SmartTRAK's Anne Staylor, Executive Editor, VP &GM of Neurotherapies, is in Barcelona attending the INS 15th Congress.

The following is just a small sampling of recent neuromodulation updates from around the world compiled, reviewed and posted daily by our SmartTRAK analysts.

Clinical Developments

• Medtronic*
• • Medtronic announced the first patient implanted in its “Evaluation of Long-term Patient Experience with a Medtronic Closed-Loop SCS System” study of its investigative, closed-loop, ECAP-responsive device to treat back and limb pain. The prospective study is enrolling 90 patients across 10 centers in Australia.
  • A University of Florida-sponsored eight patient clinical trial will evaluate DBS to treat Tourette syndrome targeting two brain regions in each hemisphere of each patient and using two leads in each hemisphere connected to two Percept PC devices. Estimated study completion is Aug 2026. clinicaltrials.gov
    
    
•  Boston Scientific*
• • Boston Scientific received FDA approval of its latest image-guided programming software, Vercise Neural Navigator with STIMVIEW XT. Developed in collaboration with Brainlab*, STIMVIEW XT provides real-time visualization of lead position and simulation modeling for Parkinson’s Disease and essential tremor treatment.

Jason Winkler, Sales VP of cybersecurity startup Device Authority, discusses the state of cybersecurity in healthcare in an interview with SmartTRAK.

To find out more, including the devices most vulnerable to cybersecurity threats and how medical device manufacturers should think about designing cybersecurity measures into their connected products, click on the following video to listen to the full interview (17:29 min). A link to download the complete transcript of the interview is also provided below.

Wallaby Medical announced it has acquired phenox GmbH, including phenox's femtos GmbH, a German-based neurovascular company, for a total of ~$545MM (EUR 500MM) including milestone payments. SmartTRAK previously reported the possibility of the acquisition deal in early March 2022. Wallaby Medical acquiring phenox GmbH is one of the largest recent cross-border transactions in the medical device industry and will enable the Company to provide a wide range of neurovascular solutions to pts in the US, China, Europe, Japan and other international markets.

For more information about phenox, click to read "phenox Takes Aim at US Market with Novel Stroke Devices", SmartTRAK's interview with James Lago, President and CEO of phenox Inc., in which he discusses the Company's novel mechanical thrombectomy device and flow diverter, and what’s next in terms of bringing these technologies to the US market.

Abbott’s Binith Cheeran, MD, PhD discusses the latest trends in DBS as well as the Company’s strategies for growth in an interview with SmartTRAK

Binith Cheeran, MD, PhD, Abbott’s senior director of medical and clinical affairs for deep brain stimulation (DBS), discusses the latest trends, research and innovation in DBS in an interview with SmartTRAK. Abbott is focused on growing the market through patient education, improving access to care through its NeuroSphere Virtual Clinic and expanding the ecosystem in DBS through the Company’s connected devices.

To find out more, including Dr. Cheeran’s thoughts on primary cell vs rechargeable devices, use of specific image guidance systems, closed-loop DBS and empowering patients through digital health solutions, click on the video below to listen to the interview recorded online via Zoom (32:45 min). A link to download the transcript of the interview is also provided below.